Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot
Institutions: Moffitt Cancer Center, Hospital Israelita Albert Einstein, The University of Texas MD Anderson Cancer Center, Aarhus University Hospital, Institut universitaire du cancer de Toulouse Oncopole, Institut Bergonié, University of Bologna, Mayo Clinic in Arizona, Hospital Universitario Fundación Jiménez Díaz, Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Oncology, D’Or Institute for Research and Education, Samsung Medical Center, Sungkyunkwan University, Bristol-Myers Squibb (United States), Institut Gustave Roussy
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405039491